Galera Therapeutics (GRTX)
OTHER OTC:GRTX
Want to see GRTX full AI Analyst Report?
Top Page
Galera Therapeutics
(OTC:GRTX)
Select Model
Select Model
Rating:50Neutral
Price Target:
$0.10
▲(400.00% Upside)
Action:Reiterated
Date:05/20/26
The score is held down primarily by weak financial performance (no revenue, ongoing operating losses, and historically negative cash flow) and limited valuation support (negative P/E, no dividend). Offsetting these are improving risk signals from the 2025 balance-sheet deleveraging, constructive technical momentum despite overbought conditions, and positive corporate developments centered on the Obsidian merger and large financing package.
Positive Factors
Merger and $350M financing
The definitive Obsidian merger plus an oversubscribed $350M private placement materially extends funding visibility into 2H 2028 and repositions Galera into a larger immuno-oncology platform. This provides durable operational runway to execute clinical milestones and de-risks near-term capital needs.
Negative Factors
Pre-revenue operating losses
Galera has been a pre-revenue biotech with zero product sales and persistent negative operating results, driving material cash burn historically. Without durable positive operating cash flow or commercialization, the company remains dependent on external financing and partner/transaction outcomes for survival.
Read all positive and negative factors
Positive Factors
Negative Factors
Merger and $350M financing
The definitive Obsidian merger plus an oversubscribed $350M private placement materially extends funding visibility into 2H 2028 and repositions Galera into a larger immuno-oncology platform. This provides durable operational runway to execute clinical milestones and de-risks near-term capital needs.
Read all positive factors
Galera Therapeutics (GRTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.07M
Dividend YieldN/A
Average Volume (3M)63.57K
Price to Earnings (P/E)―
Beta (1Y)1.82
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding160,429,780
10 Day Avg. Volume87,114
30 Day Avg. Volume63,573
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.36
Enterprise Value/Market Cap0.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.35
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Galera Therapeutics Business Overview & Revenue Model
Company Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese ...
How the Company Makes Money
null...
Galera Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
28
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -3.84M | -259.00K | -114.00K | -778.00K |
| EBITDA | -6.04M | -20.16M | -70.24M | -50.61M | -72.56M |
| Net Income | 149.05M | -18.96M | -59.08M | -62.22M | -80.53M |
Balance Sheet | |||||
| Total Assets | 7.20M | 10.10M | 26.14M | 44.04M | 83.31M |
| Cash, Cash Equivalents and Short-Term Investments | 6.38M | 8.29M | 18.26M | 31.60M | 71.22M |
| Total Debt | 0.00 | 151.05M | 1.25M | 44.00K | 302.00K |
| Total Liabilities | 645.00K | 153.77M | 157.33M | 153.22M | 141.31M |
| Stockholders Equity | 6.55M | -143.67M | -131.19M | -109.18M | -58.00M |
Cash Flow | |||||
| Free Cash Flow | -6.05M | -12.14M | -44.91M | -43.45M | -68.24M |
| Operating Cash Flow | -6.05M | -12.14M | -44.85M | -43.43M | -67.96M |
| Investing Cash Flow | 3.50M | -46.00K | 27.29M | 23.99M | 5.24M |
| Financing Cash Flow | 635.00K | 2.22M | 31.50M | 3.89M | 66.71M |
Galera Therapeutics Technical Analysis
Positive
0.02
Price Trends
0.07
Positive
0.05
Positive
0.04
Positive
Market Momentum
<0.01
Positive
63.05
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRTX, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.07, and below the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 63.05 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRTX.
Galera Therapeutics Risk Analysis
Galera Therapeutics disclosed 47 risk factors in its most recent earnings report. Galera Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Galera Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $34.03M | -2.13 | -77.90% | ― | 127.03% | 87.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $16.07M | -0.69 | 13.71% | ― | ― | ― | |
44 Neutral | $1.60M | -0.20 | ― | ― | 99.48% | -474.47% | |
| ― | $1.42M | -0.56 | -263.57% | ― | -61.81% | 99.68% |
* Healthcare Sector Average
GRTX
Galera Therapeutics
0.10
0.08
316.67%
QCLS
Q/C Technologies
4.18
-13.11
-75.82%
SCNI
Scinai Immunotherapeutics
0.46
-2.30
-83.30%
EVAX
Evaxion Biotech
4.08
1.72
72.88%
ONCO
Onconetix
1.24
-306.89
-99.60%
Galera Therapeutics Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Galera Therapeutics Eliminates Series B Preferred, Simplifies Equity
Positive
May 19, 2026
On May 15, 2026, Galera Therapeutics, Inc. converted its remaining 42,839.11 shares of Series B Non-Voting Convertible Preferred Stock into 42,839,103 shares of common stock in accordance with its governing certificate of designation. The company ...
Business Operations and StrategyShareholder Meetings
Galera Therapeutics Expands Share Authorization, Enhances Stockholder Rights
Neutral
May 15, 2026
On May 11, 2026, Galera Therapeutics doubled its authorized common stock from 200 million to 400 million shares through a charter amendment approved by stockholders at the company’s May 8, 2026 annual meeting. This move significantly expands...
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
Galera Shareholders Approve Governance Changes and Share Increase
Positive
May 11, 2026
At its combined 2025 and 2026 Annual Meeting of Stockholders held on May 8, 2026, Galera Therapeutics’ shareholders elected one Class III director to serve until the 2028 annual meeting and two Class I directors to serve until the 2029 annua...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing
Galera Announces Obsidian Merger and $350M Financing
Positive
Apr 14, 2026
On April 14, 2026, Galera Therapeutics and privately held Obsidian Therapeutics announced a definitive all-stock merger agreement under which both companies will become subsidiaries of a newly formed parent that will operate as Obsidian Therapeuti...
Private Placements and Financing
Galera Therapeutics Announces Share Conversions and Warrant Exercise
Neutral
Apr 9, 2026
On April 7, 2026, Galera Therapeutics, Inc. converted 76,479.175 shares of its Series B Non-Voting Convertible Preferred Stock into 76,479,164 shares of common stock, paying cash in lieu of fractional shares and leaving 42,839.11 Series B Preferre...
Regulatory Filings and ComplianceShareholder Meetings
Galera Sets Deadlines for 2026 Combined Annual Meeting
Neutral
Apr 3, 2026
Galera Therapeutics has scheduled its combined 2025 and 2026 Annual Meeting of Stockholders for May 8, 2026, after its 2024 annual meeting was held on February 24, 2025, and is updating key deadlines for shareholder participation as a result of th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.